Podcasts about Accreditation

This episode—recorded live at Becker's 31st Annual The Business and Operations of ASCs event—features Dr. Ken Grubbs, Executive Vice President, Accreditation and Certification Operations, and Chief Nursing Officer, Joint Commission. He discusses how Accreditation 360 is shaping the future of healthcare quality, reducing administrative burden, and promoting collaboration to improve patient outcomes.This episode is sponsored by Joint Commission.

This episode—recorded live at Becker's 31st Annual The Business and Operations of ASCs event—features Dr. Ken Grubbs, Executive Vice President, Accreditation and Certification Operations, and Chief Nursing Officer, Joint Commission. He discusses how Accreditation 360 is shaping the future of healthcare quality, reducing administrative burden, and promoting collaboration to improve patient outcomes.This episode is sponsored by Joint Commission.

As we kickoff season 6 of the podcast, we feature co-authors of Foundations of Assessment: From Theory to Practice, a recently released book from Routledge. Our guests are Joe Levy and Natasha Jankowski. Joe is Associate Vice Provost of Accreditation and Quality Improvement at Excelsior University. Natasha is Director of the Center for Excellence in Teaching and Learning at the University of Wisconsin-Milwaukee. Link to resources mentioned in this episode:Foundations of Assessment: From Theory to Practicehttps://www.routledge.com/Foundations-of-Assessment-From-Theory-to-Practice/Levy-Jankowski/p/book/9781032581569  This season of Leading Improvements in Higher Education is sponsored by the Center for Assessment and Research Studies at James Madison University; learn more at jmu.edu/assessment. Episode recorded: September 2025.  Host:  Stephen Hundley.  Producers:  Chad Beckner and Angela Bergman.  Original music:  Caleb Keith.  This award-winning podcast is a service of the Assessment Institute in Indianapolis; learn more go.iu.edu/assessmentinstitute.

Nurses Out Loud with Jodi O'Malley MSN, RN – Unsafe staffing puts patients and nurses at risk — and now, hospitals face real consequences. Beginning in 2026, the Joint Commission's new National Performance Goals require proof of adequate, competent nurse staffing. Facilities that fail to meet safe staffing standards could lose their accreditation and Medicare funding, signaling a major shift toward healthcare accountability...

Nurses Out Loud with Jodi O'Malley MSN, RN – Unsafe staffing puts patients and nurses at risk — and now, hospitals face real consequences. Beginning in 2026, the Joint Commission's new National Performance Goals require proof of adequate, competent nurse staffing. Facilities that fail to meet safe staffing standards could lose their accreditation and Medicare funding, signaling a major shift toward healthcare accountability...

Joint Commission is rolling out Accreditation 360, a major update to hospital standards that takes effect January 1, 2026. In this episode of Healthcare Facilities Network, Jim Grana, Life Safety Code Field Director at Joint Commission, walks us through what these changes mean for hospitals and healthcare teams across the U.S.Jim explains how the standards are being restructured, including a nearly 50% reduction in Elements of Performance for some hospitals, and offers practical guidance on how organizations can prepare. From understanding the new numbering system to identifying what's critical for compliance, this episode makes Accreditation 360 clear and actionable.Whether you're directly involved in hospital compliance or just curious about how these updates impact healthcare operations, Jim provides insight, strategies, and perspective to help teams stay ahead of the changes.

Bill Zimmerman is an assistant teaching professor in the department of advertising and public relations in the Donald P. Bellisario College of Communications at Penn State. He's the author of “Understanding the Creator Economy: Making Digital Media Work for You,” published by Kendall Hunt. He teaches courses such as Digital PR and PR Campaigns, and in the spring semester will offer Digital Content and the Creator Economy, a new course launching Penn State's content creator certificate program. Prior to teaching, he worked as a newspaper reporter and public relations professional in higher education. He also holds the Accreditation in Public Relations.

Australia faces an engineering shortage, yet many migrant engineers are underemployed. Learn about qualification recognition, job search tips, CV advice, and networking strategies. - آسٹریلیا میں انجنیئرز کی کمی کا سامنا ہے، لیکن بہت سے تارکین وطن انجینئر اپنی قابلیت سے کم اہلیت کی ملازمت کر رہے ہیں۔ اپنی قابلیت کی توثیق کے بارے میں معلومات حاصل کریں، ملازمت تلاش کرنے کی تجاویز، سی وی مشورے، اور نیٹ ورکنگ کی حکمت عملیوں کے بارے میں جانیں۔

Australia faces an engineering shortage, yet many migrant engineers are underemployed. Learn about qualification recognition, job search tips, CV advice, and networking strategies. - ஆஸ்திரேலியாவில் பொறியியல் துறையில் பணியாளர் பற்றாக்குறை நிலவுகிறது, ஆனால் பல புலம்பெயர்ந்த பொறியாளர்கள் தகுந்த வேலை வாய்ப்புகளை பெற முடியாமல் உள்ளனர். இந்தப்பின்னணியில் பொறியியல் பணிக்கான தகுதிச் சான்றிதழ் அங்கீகாரம், வேலை தேடல் குறிப்பு, சுயவிவர (CV) ஆலோசனைகள் மற்றும் தொழில்முறை தொடர்புகளை உருவாக்கும் முறைகள் குறித்து அறிந்துகொள்வோம்.

Australia faces an engineering shortage, yet many migrant engineers are underemployed. Learn about qualification recognition, job search tips, CV advice, and networking strategies. - ඕස්ට්‍රේලියාවේ මේ වනවිට ඉංජිනේරු වෘත්තිකයින්ගේ හිඟයකට මුහුණ දී සිටියත්, බොහෝ සංක්‍රමණික ඉංජිනේරුවන් රැකියා විරහිතව සිටින බව වාර්තා වේ. සුදුසුකම් හඳුනා ගැනීම, රැකියා සෙවීමේ උපදෙස්, CV සඳහා වන උපදෙස් සහ networking උපාය මාර්ග ගැන ඉගෙන ගැනීම මේ හේතුවෙන් වැදගත් වේ

Australia faces an engineering shortage, yet many migrant engineers are underemployed. Learn about qualification recognition, job search tips, CV advice, and networking strategies.

Behind the Screen: The Impact of Cyberbullying on Adolescents and Teens Evaluation and Credit:  https://www.surveymonkey.com/r/medchat83 Target Audience             This activity is targeted toward primary care physicians and advanced providers. Statement of NeedThis will be a two-part podcast that will focus on the psychological effects of cyberbullying and AI companions. This will be specific to adolescents and teens. As a result of the growing prevalence in digital engagement, a by-product has been cyberbullying. The psychological effects of cyberbullying are unique in that they differ from traditional bullying due to the anonymity and permanence. Additionally, with the growing popularity of AI companions a second podcast will address this topic. Both podcasts will address the psychological effects and provide tools for providers to use to screen for subtle signs as well as resources. Objectives  Define cyberbullying and distinguish its varying levels of severity. Describe the psychological effects of cyberbullying and differentiate its impact from traditional bullying in pediatric populations. Identify clinical indicators, behavioral signs and psychosocial cues that may suggest that a patient is a victim of cyberbullying. Moderator Mark McDonald, M.D., MHA, CPE System Vice President Pediatric Medical Affairs Norton Healthcare Medical Director, Norton Children's Professor, University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Critical Care SpeakerMichael Eiden, PhD, LCSW, LCADC, CSAT, CCS Licensed Clinical Social Worker Licensed Clinical Alcohol and Drug Counselor Certified Sex Addiction Therapist Certified Clinical Supervisor Board Certified Sex Therapist EMDR Trained Eiden Integrative Counseling   Planner and Moderator Disclosures  The planners, moderator and speaker of this activity do not have any relevant financial relationships with ineligible companies to disclose. Commercial Support There was no commercial support for this activity.  GrantThis episode is supported by a grant from the Kentucky Medical Association's ‘Small STEPS, Big Impact' campaign, a two-year initiative that encourages patients to achieve long-term success through taking simple steps that can add up to make a big impact on their health. The campaign focuses on five key areas (screenings, tobacco use, exercise & nutrition, physician visits and stress) and offers straightforward strategies and support for patients. It is a partnership between the KMA and its charitable arm, the Kentucky Foundation for Medical, made possible by a grant from the Kentucky Department for Public Health. For more information, visit SmallSTEPSKy.org.     Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing CreditsNorton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.50 ANCC CE contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.     For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Social Worker CreditsThis activity will provide .50 hours of required continuing education units. National Association of Social Workers, Kentucky Chapter (NASW-KY) is an approved provider for social work credits through the Kentucky Board of Social Work. NASWKY#06/30/25. For information about social worker credits, please send an email tocme@nortonhealthcare.org.   Resources for Additional Study/References Internet Addiction Assessment (IAA) https://psychology-tools.com/test/internet-addiction-assessment Parent Tools – Operation Parent https://www.operationparent.org/ Parent Tools – Children and Screens https://www.childrenandscreens.org/ Adverse Childhood Experiences and Early Adolescent Cyberbullying in the United States https://pubmed.ncbi.nlm.nih.gov/36443937/ Social Epidemiology of Early Adolescent Cyberbullying in the United States https://pubmed.ncbi.nlm.nih.gov/35840085/   SmallSTEPSKy.org   Date of Original Release | Oct. 2025; Information is current as of the time of recording.  Course Termination Date | Oct. 2027 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org   Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope. Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

Episode: 00287 Released on October 6, 2025 Description: In this episode of Analyst Talk with Jason Elder, retired Director of State Operations for New York's Crime Analysis Center Network, John Riegert, shares how a handful of analysts grew into a statewide intelligence powerhouse connecting 57 counties. Drawing from 40 years in law enforcement, including his time as a captain with Troy PD, John discusses the evolution of crime analysis in New York from data struggles and building legitimacy to creating analyst certifications, promoting leadership opportunities, and balancing privacy with real-time policing needs. His insights reveal how the profession matured into an essential pillar of modern public safety.

“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53

This week, we're joined by Jenna Kokoski, a BCBA with over 20 years of experience in the ABA field. Jenna is the COO of Jade Health and a leader in the ABA community, known for her advocacy, expertise, and dedication to creating ethical and sustainable business models. She's here to talk about the importance of accreditation in ensuring quality care in ABA, what families should look for in a provider, and how accreditation benefits both families and individuals with autism. Download to learn more!  Resources  Jade Health's Suite of Offerings Include: BHCOE Accreditation |National Autism Data Registry | Credentialing and Contracting | Jade Health Learning Hub | Quickstart ABA   Schedule a Meeting  Connect on Social Media ............................................................... Autism weekly is now found on all of the major listening apps including apple podcasts, stitcher, Spotify, amazon music, and more. Subscribe to be notified when we post a new podcast. Autism weekly is produced by ABS Kids. ABS Kids is proud to provide diagnostic assessments and ABA therapy to children with developmental delays like Autism Spectrum Disorder. You can learn more about ABS Kids and the Autism Weekly podcast by visiting abskids.com.  

This program, led by Christiaan Scott, MD, Professor of Pediatric Rheumatology at the University of Ottawa and Raphaella Stander, MBCHB, Pediatrician at Atlantic Children's Practice, focused  on three case studies to provide physicians with education on best practices to: 1) suspect and diagnose FOP, 2) monitor and manage younger children with FOP, and 3) monitor and manage older children and adults with FOP. This accredited CME program provides healthcare professional with timely and practical education on fibrodysplasia ossificans progressiva (FOP). It is supported by an educational grant from Ipsen Biopharmaceuticals.To obtain CME credit, visit https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pediatrics, rheumatology, genetics, family medicine, and orthopedics. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Apply best practices for suspecting and diagnosing FOP.List best practices for managing young children with FOP.Identify best practices to manage older children and adults with FOP.Christiaan Scott, Professor of Medicine, University of OttawaRaphaella Stander, MBCHB, Pediatrician, Atlantic Children's PracticeDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses the following relevant financial relationships with ineligible companies:Grant/Research Support: Regeneron*, Incyte*, Janssen*, Roche*; Speaker's Bureau:  Ipsen*, Regeneron*, Springer*, Jannsen**Relationships have endedDr. Stander has no relevant financial relationships with ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

In this episode, hear from Brian Polk, Director of Accreditation at the Society for Classical Education. Learn about how SCL is doing accreditation with a view to helping classical schools flourish. Find out more about what it looks like to have a visiting team at your school and steps you can take to explore accreditation through SCL.Links from this episode:SCL Accreditation webpagePrevious episode: AccreditationThe Educational Renaissance Podcast is a production of ⁠⁠⁠⁠⁠Educational Renaissance⁠⁠⁠⁠⁠ where we promote a rebirth of ancient wisdom for the modern era. We seek to inspire educators by fusing the best of modern research with the insights of the great philosophers of education. Join us in the great conversation and share with a friend or colleague to keep the renaissance spreading.Take a deeper dive into training resources produced by Educational Renaissance such as Dr. Patrick Egan's new book entitled Training the Prophetic Voice available now through ⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon⁠⁠⁠⁠⁠⁠⁠⁠⁠.

A simple, must-know guide to ARC-PA terms, probation vs. provisional, and how to vet programs before you hit submit. This is exactly what you need to know when it comes to PA program accreditation and applying to PA schools!CASPA SOS: Last Call Bootcamp — your step-by-step plan to submit (or strengthen) your PA school app before any more deadlines hit. Happening October 12 >> Walk in confused, walk out with a prioritized checklist, expert feedback, and a clear next step for your stage—submitted, not yet, or next cycle!Be the one who gets interviews, not rejections!→ Join now here! We can't wait to see you there! Keep up the amazing work, future PA! Beth & Katie

“I think sometimes people don't expect pediatric patients to handle radiation as well as they do. They may have a family member who also had radiation for breast cancer or for prostate cancer and they were an older adult and had really severe side effects. And then they say, ‘Oh, no, I've got to put my little baby through this. I don't really want to do this.' We say kids are very different in how they handle this. They're very resilient, so we can provide good education about that,” Elizabeth Cummings, MSN, CPNP-AC, CPHON®, radiation oncology nurse practitioner at Children's Hospital of Philadelphia in Pennsylvania, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation treatment care for pediatric patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to radiation oncology treatment care for pediatric patients. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 365: Radiation-Associated Secondary Cancers Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 204: How Radiation Is Used in Palliative Care Episode 50: Difficult Decisions in Childhood Cancer ONS Voice articles: Fertility Preservation Protects Possibilities for Patients With Cancer Have Meaningful Conversations With Pediatric, Adolescent, and Young Adult Patients and Their Families Pediatric Cancer Survivors Require Additional Care and Monitoring Prepare Survivors for the Risk of Secondary Cancers Secondary Cancers in Pediatric Survivors ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS courses: Essentials in Survivorship Care for the Advanced Practice Provider ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiation Therapy Survivorship: Healthcare Providers' Perspectives on Education and Care Radiation Therapy: Understanding the Patient Experience Reducing Pediatric Patient Anxiety: Implementing a Nonpharmacologic Intervention to Aid Patients Undergoing Radiation Therapy Other ONS Resources Inclusive Care Learning Library Late Effects of Cancer Treatment Huddle Card Proton Therapy Huddle Card Radiation Huddle Card Radiation Learning Library Oncolink Jr. Pediatric Radiation Oncology Society  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “I think one of the things to think about with kids is sometimes they're not as forthcoming with what's going on, and sometimes it's a little bit harder to understand. Sometimes that's just because developmentally, they're much younger. A 1-year-old can't exactly tell you what's wrong. And so you're really trying to figure it out based on their cues versus a teenager who can tell you, but maybe they're too embarrassed about something in a way that an adult might not be.” TS 7:01 “Child life specialists are incredible. ... They provide age-appropriate education and explanations for patients, so talking to a 3-year-old about cancer is very different from an 8-year-old or even a teenager. They really are able to meet each patient exactly where they are and at the level that they are, and then provide the appropriate amount of information, which is so helpful for a patient since they learn to build trust and cope with their treatment and [they feel like they] have somebody who can relay that information in a clear and concise way.” TS 11:16 “There's certainly growing concern about the potential effects of anesthesia on brain health, especially in a vulnerable population like very young children, which are the ones who need anesthesia. We really try to mitigate this by optimizing our anesthetic agents, so we'll use propofol, which has a really quick onset and offset. And even when the radiation treatment is done, they'll stop the propofol in the radiation room—even though they are still walking back to recovery, just to minimize the amount of time that it's on—and trying to use the lowest dose possible. We also [explore] a lot of nonanesthetic strategies, [like] child life support, trying to introduce video distraction when we can, and having music and audiobooks.” TS 17:47 “[In] pediatrics, the patient, not the parent, is your patient. And that can look really different for a 3-year-old versus a 17-year-old. Somebody who can't officially sign consent, but they certainly have a lot of buy-in about the things that reach their body, versus a 3-year-old, where the parents are really taking ownership of that. I think sometimes it's tricky in the world of pediatrics as we think about the ethics of ‘Who are we training here? Is it the patients? Is it the parents?' And we continue to advocate for our patients.” TS 23:32 “I think that pediatric patients still want to be normal kids. They still want to do their normal activities. ... Our pediatric patients, a lot of times, have healthier tissues. They haven't seen as much wear and tear. They haven't developed the bad habits of some adults. They don't have the same environmental exposures, they're not smoking, they probably have fewer comorbidities. ... They're a different population. ... They're just amazing. They still want to be a kid, they still want to go to school, they still want to be with their friends. It's really encouraging to see that.” TS 36:03 

Cameron is joined by Jennifer Hartley, founder of Skin Synthesis, who shares her journey from critical care nursing to establishing her own aesthetics practice. They discuss the challenges of launching a business during the pandemic, the importance of continuous education, networking, and the philosophy behind her practice that focuses on natural results and building long-term relationships with patients. Jennifer also reflects on humbling moments in her practice and the significance of honesty and boundaries in patient care, as well as the role of technology in enhancing patient experiences.Cameron and Jennifer talk about the importance of building strong patient relationships, elevating treatment planning, and the significance of legal compliance in aesthetic practices. They emphasize the need for intentional learning at conferences and prioritizing patient care over profits,. The dialogue highlights the balance between business acumen and patient-centered care in the medical aesthetics industry.Listen In!Thank you for listening to this episode of Medical Millionaire!Takeaways:Jennifer transitioned from critical care to aesthetics to help people live well.The hustle of entrepreneurship requires grit and dedication.Investing in education is crucial for success in aesthetics.Networking is essential for support and growth in the industry.Skin Synthesis focuses on natural results and long-term patient relationships.Humbling moments in aesthetics can be profoundly impactful.Honesty and setting boundaries with patients is vital.Technology plays a significant role in enhancing patient communication.The pandemic presented unique challenges for launching a business.Confidence restoration is a key aspect of aesthetic practice. Building relationships is key to patient loyalty.Follow-up communication enhances patient retention.Elevating treatment plans can improve patient experience.Intentional learning at conferences leads to actionable insights.Legal compliance is crucial for aesthetic practices.Prioritizing patient care can lead to long-term success.Investing in team training is essential for growth.Understanding financials is important but shouldn't overshadow patient care.Accreditation can raise industry standards.Continuous passion for aesthetic medicine is vital for success.Unlock the Secrets to Success in Medical Aesthetics & Wellness with "Medical Millionaire"Welcome to "Medical Millionaire," the essential podcast for owners and entrepreneurs inMedspas, Plastic Surgery, Dermatology, Cosmetic Dental, and Elective Wellness Practices! Dive deep into marketing strategies, scaling your medical practice, attracting high-end clients, and staying ahead with the latest industry trends. Our episodes are packed with insights from industry leaders to boost revenue, enhance patient satisfaction, and master marketing techniques.Our Host, Cameron Hemphill, has been in Aesthetics for over 10 years and has supported over 1,000 Practices, including 2,300 providers. He has worked with some of the industry's most well-recognized brands, practice owners, and key opinion leaders.Tune in every week to transform your practice into a thriving, profitable venture with expert guidance on the following categories...-Marketing-CRM-Patient Bookings-Industry Trends Backed By Data-EMR's-Finance-Sales-Mindset-Workflow Automation-Technology-Tech Stack-Patient RetentionLearn how to take your Medical Aesthetics Practice from the following stages....-Startup-Growth-Optimize-Exit Inquire Here:http://get.growth99.com/mm/

Accreditation sits at the heart of higher education's promise to deliver value, quality, and opportunity. But in 2025, the landscape is shifting fast, fueled by questions of accountability, the rise of alternative accreditors, and new expectations around data and student success. In this episode of CCA on the Air, we sit down with Dr. Maria Toyoda, the new President and CEO of WSCUC. Together, we explore how WSCUC is using data to drive innovation, the role of accreditation in the evolving higher education landscape, and how accreditors can balance rigorous standards with access, student success, and innovation.

It's YOUR time to #EdUpIn this episode, part of our Academic Integrity Series, sponsored by ⁠Pangram Labs,⁠YOUR guest is ⁠Dr. Heather Perfetti, President & CEO, Middle States Commission on Higher EducationYOUR cohost is ⁠Bradley Emi , ⁠Cofounder & CTO, ⁠Pangram Labs⁠YOUR host is ⁠Elvin Freytes⁠How does Dr. Perfetti define academic integrity through the lens of accreditation standards & why does she emphasize centering students around academic rigor & holistic learning experiences? What makes Middle States Commission unique as a global institutional accreditor serving over 500 institutions worldwide & how do they work as part of the regulatory triad? How is Dr. Perfetti supporting institutions navigating AI integration while maintaining academic integrity & transparency in their accreditation processes?Listen in to #EdUpThank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠& ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dr. Joe Sallustio⁠⁠⁠⁠⁠● Join YOUR EdUp community at ⁠The EdUp Experience⁠We make education YOUR business!P.S. Want to get early, ad-free access & exclusive leadership content to help support the show? Then ⁠⁠​subscribe today​⁠⁠ to lock in YOUR $5.99/m lifetime supporters rate! This offer ends December 31, 2025!

This week we sit down with Lauren Bozich, MS, RD, LDN, Senior Director of Accreditation at ACEND. This episode provides an important update since our conversation with Dr. Rayane AbuSabha last year. Starting this year, all supervised practice and graduate programs accredited through ACEND must follow the new DICAS application process.Bozich walks us through the changes, explaining key dates, what they mean for students, how to prepare strong applications, and the overall benefits of this streamlined system. With her expertise, listeners will gain clarity and confidence in navigating this transition.For more details, visit ACEND's website: https://www.eatrightpro.org/acend/students-and-advancing-education/students-and-advancing-education-intro

In this episode of the Alliance Podcast, Alliance Podcast Task Force Member Andrea Zimmerman, EdD, CHCP, chats with Accreditation Council for Continuing Medical Education (ACCME) Vice President of Accreditation and Recognition Dion Richetti about accreditation myths and misconceptions that can hinder creativity and diversity in continuing education. Listen in to learn how accreditation bodies can support innovative programming while still ensuring compliance.|| LINKSAlmanac: Home | Alliance: Alliance for Continuing Education in the Health Professions | Alliance LinkedIn: Alliance For Continuing Education in the Health Professions: Posts | LinkedIn | AACME: Accreditation Council for Continuing Medical Education - ACCME | AACME LinkedIn: Accreditation Council for Continuing Medical Education (ACCME): Overview | LinkedIn | ACCME Facebook: Facebook | ACCME Instagram: https://www.instagram.com/accreditedcme | AACME Bluesky: Accreditation Council for ContinuingMedical Education (@accreditedcme.bsky.social) — Bluesky | ACCME Compliance Check Archive: News Archive - ACCME | “Coffee with Graham” Podcast: Podcast - ACCME | ACCME Compliance & Noncompliance: Compliance & Non Compliance - ACCME | ACCME Policies: Policies - ACCME | Dion Richetti LinkedIn: Dion Richetti | LinkedIn

Third week of September, what'd you miss in vet med?NY Lawmakers propose AG Oversight on AcquistionsLMU Orange Park receives COE AccreditationGallant brings education to PractionersEmbrace Pet Insurance ScholarshipTribute to my dog WalterHelpful links:The Bird Bath substackNVA: Associate Veterinarian Humber Veterinary Clinic - Job Description

The accredited CME program highlights the latest clinical research about hemophilia, a rare, genetic bleeding disorder. Led by Dr. Steven Pipe, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with hemophilia. This program is supported by an educational grant from Sanofi.To receive CME credit, visit https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hemophilia. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with hemophilia and its clinical relevance.Steven Pipe, MDProfessor of Medicine,University of Michigan Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Pipe discloses the following relevant financial relationships with ineligible companies:Consultant: Bayer, BioMarin, CSL Behring, Hema Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Poseida Therapeutics, Roche/Genentech, Sanofi, Takeda, Spark TherapeuticsScientific Advisory Committee: GeneVentiv, Equilibra BioscienceGrant/Research Support: Siemens, YewSaving Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This accredited CME program highlights the latest clinical research about immune thrombocytopenia (ITP), a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this program provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in ITP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with ITP and its clinical relevance.FacultyShruti Chaturvedi, MDAssistant Professor of Medicine,Johns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

The accredited CME program highlights the latest clinical research about iTTP, a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in iTTP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with iTTP and its clinical relevance. Shruti Chaturvedi, MDAssistant Professor of MedicineJohns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

We break down the core Circumplex orientation - Satisfaction (growth) vs Security (protection). Learn how state of mind drives behavior, why confidence is quiet, and practical ways to shift from defensiveness to growth. View the full show notes here: https://www.human-synergistics.com.au/resources/culture-insights-blog/satisfaction-vs-security-what-it-is-and-why-it-matters-culture-bites-248/ Consulting Solutions: https://www.human-synergistics.com.au/our-services/consulting/ Diagnostics: https://www.human-synergistics.com.au/our-diagnostics/ Accreditation: https://www.human-synergistics.com.au/become-accredited/

  “One powerful, overlooked aspect of colorectal cancer survivorship is the emotional and identity transformation that our survivors undergo—and really how little space is given in the clinical arena for that. No one really talks about this ‘invisible recovery.' Facing mortality can lead to prolonged changes is values, relationships, and life goals. And these experiences aren't captured in lab results or imaging scans, but they really shape how survivors live, love, and heal and continue with their lives,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 12, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase is knowledge related to colorectal cancer survivorship nursing considerations. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 374: Colorectal Cancer Treatment Considerations for Nurses Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing article: Closing the Gaps: Addressing the Unmet Needs of Cancer Survivors Oncology Nursing Forum articles: Symptom Occurrence, Frequency, and Severity During Acute Colorectal Cancer Survivorship The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS Survivorship Care Plan Huddle Card ONS Learning Libraries: Colorectal cancer Survivorship Academy of Oncology Nurse and Patient Navigators American Cancer Society National Colorectal Cancer Roundtable Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer Resource Library Livestrong at the YMCA Pan Ohio Hope Ride To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “As of the most recent data, more than 1.5 million people in the United States are living as colorectal cancer survivors. So this includes not only those who are currently undergoing active cancer treatment but also those who have completed treatment and ultimately are hopefully in remission. Just a reminder that colon cancer is the third most commonly diagnosed cancer in the United States and it's the fourth leading cause of cancer-related deaths.” TS 1:53 “Our colorectal cancer survivors may have significant barriers when receiving this comprehensive survivorship care, and these challenges can affect not only their physical recovery but their emotional well-being and, ultimately, their long-term health outcomes. We as oncology nurses do play a pivotal role in identifying and addressing these barriers. So these can include fragmented care. Who's caring for these patients? That care coordination between the oncologist and the oncology team and then the primary care providers and team. Limited access—so our patients that may have geographic limited access or also financial- or insurance-related obstacles to follow-up services.” TS 9:10 “Our nurses can also facilitate the communication between specialists and primary care providers, so making sure that we're sending records, keeping those lines of communications open. Also, nurses can provide that psychosocial support, so our screening for distress and also advocating and supporting for referral to counseling or support groups for a patient. Nurses can also act as navigators to guide these patients through complex care systems.” TS 11:21 “Some of the recommended changes—nutrition—enhancing and emphasizing fruits, vegetables, that colorful plate, with whole grains. Limit those red and processed meats, and reduce sugary drinks and alcohol. I know we will all have those patients who have read things or cancer myths about, ‘Oh, cancer feeds on sugar, so I shouldn't drink anything or eat anything with sugar,' and maybe addressing that, just really emphasizing the well-rounded meals.” TS 19:57 “When we think about [ourselves], ‘Well, I don't have an implicit bias,' but we may not think about what that is. Some common preconceived assumptions are that survivorship equals a cure. And this assumption may overlook that chronic symptoms or those late effects and emotional needs of long-term survivors. So knowing that when a patient is coming to us on surveillance, they may be cured; they may not have active cancer, but they're still dealing with some of those chronic symptoms—and acknowledging that.” TS 30:37 “There's an assumption that an ostomy equals poor quality of life, and this may stigmatize patients and discourage open conversations about adaptation and support. A couple weeks ago, I volunteered at the Pan Ohio Hope Ride, which is with the American Cancer Society, and several states have a ride that's similar. And there was a patient riding, and I could tell over his jersey that he had an ostomy bag underneath that. And I just looked at him and I thought, ‘That's amazing. You are still functioning, still living, still riding a bike throughout the entire state of Ohio with an ostomy.' So he's still having that good quality of life. That doesn't stop him from living.” TS 31:39

Host Jeremy C. Park talks with Jim Bartoo, Marketing and Public Relations Director with Nashville Zoo, who discusses the zoo's history, growth and development, and commitment to animal welfare, along with the importance of accreditation by the Association of Zoos & Aquariums. He highlights the zoo's conservation efforts, both local and global, as well as their educational programs and upcoming events. The conversation also covers the zoo's unique features, including exhibit design and animal care, and ways for the public to support and enjoy the zoo's experiences.Nashville Zoo's Philosophy and DevelopmentsDuring the interview, Jim provides an overview of Nashville Zoo's history, location, and recent developments. He explains that the zoo, which moved to its current location in 1996, has been built from the ground up, allowing for the implementation of the latest philosophies and technologies for animal care and habitat development. Jim also discusses the shift in zoo philosophy from focusing on cleanliness and sterilization to prioritizing animal welfare and creating environments that promote animal happiness and comfort.Importance of AZA Accreditation for ZoosJim discusses the importance of accreditation by the Association of Zoos & Aquariums (AZA) for zoos in the United States. He explains that while all zoos must have a USDA license for animal care, AZA accreditation goes well beyond the minimum standards, focusing on animal health, veterinary care, education, and conservation efforts. This accreditation is a gold standard for animal care and is required every five years as the standards evolve. Jim emphasizes that AZA accreditation is crucial for visitors to ensure they are supporting zoos that prioritize animal welfare.Nashville Zoo's Conservation and Education EffortsJim discusses Nashville Zoo's conservation efforts, which include local and global initiatives. The zoo works with organizations like TWRA and USDA to protect streams and environments in Tennessee, conducting head start programs and monitoring waterways. Internationally, they study animal migration patterns, such as giraffe movements in Africa, to address habitat fragmentation issues. The zoo also focuses on education, offering programs for all ages and taking ambassador animals to schools and nursing homes.Nashville Zoo Upcoming EventsJim also highlights upcoming events at Nashville Zoo, including the upcoming opening of a new exhibit, Leopard Forest, the Zzzoofari Slumber camp out on May 24, Brew at the Zoo on June 13, and Summer Splash Saturdays in July and August. Jim encourages public support through memberships, donations, and corporate sponsorships to help fund new exhibits and conservation work.Visit https://www.nashvillezoo.org to learn more.

Alzheimer's Disease Early Diagnosis and Management Evaluation and Credit:  https://www.surveymonkey.com/r/medchat82   Target Audience             This activity is targeted toward primary care physicians and advanced providers. Statement of Need A special report of Alzheimer's Disease Facts and Figures published in 2017, indicated 4 out of 5 Americans would want to know if they had Alzheimer's disease before it impacted their life. With the aging population the incidence of Alzheimer's is growing, according to the Alzheimer's Association over 7 million Americans are living with AD. This program will focus on screening and dx of AD in the early stages especially in pc offices, where patients will first present with cognitive symptoms. Additionally, this podcast will highlight the new blood biomarker test recently approved and its indications. Objectives  Differentiate between normal cognitive aging, mild cognitive impairment and early-stage Alzheimer's disease. Identify appropriate cognitive screening tools for use in primary care and their role in the early identification of Alzheimer's disease. Explain the mechanism and clinical relevance of blood-based biomarkers in the diagnosis of Alzheimer's disease, including the current guidelines and emerging practices. ModeratorRachel Hart, D.O. Geriatric Medicine Physician Memory and Cognitive Disorders Specialist Norton Neuroscience Institute Memory Center SpeakerGreg E. Cooper, M.D., Ph.D. Chief, Adult Neurology Medical Director, Memory Center Norton Neuroscience Institute   Planner Disclosure  The planners of this activity do not have any relevant financial relationships with ineligible companies to disclose. Moderator and Speaker DisclosureThe moderator, Gregory Cooper, M.D., Ph.D., discloses relevant financial relationships with Eli Lilly and Eisai (research). The speaker, Rachel Hart, D.O., discloses a relevant financial relationship with Eli Lilly (faculty).  All relevant financial relationships have been successfully mitigated. Commercial Support  There was no commercial support for this activity.  Physician CreditsAccreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Credits Norton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.50 ANCC CE contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.   For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org.   Resources for Additional Study/ReferencesAmerican Perspectives on Early Detection of Alzheimer's Disease in the Era of Treatment https://www.alz.org/alzheimers-dementia/facts-figures   Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care https://pubmed.ncbi.nlm.nih.gov/39068545/   Date of Original Release | Sept. 2025; Information is current as of the time of recording.  Course Termination Date | Sept. 2028 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope. Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

“

“All of these TKIs [tyrosine kinase inhibitors] inhibit BCR-ABL1 in some way, shape, or form. When BCR-ABL1 is mutated, it has uncontrolled tyrosine kinase activity, leading to rapid cell proliferation. When we then inhibit that BCR-ABL1 that's been mutated, we disrupt this abnormal signaling pathway that drives CML [chronic myeloid leukemia] cell proliferation and survival, ultimately leading to decreased cancer cell growth, increased apoptosis or cell death, and potentially inducing a disease remission,” Samantha Maples, PharmD, BCOP, clinical pharmacy specialist supervisor for hematology and cellular therapy at Allegheny Health Network in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the BCR-ABL1 inhibitor drug class.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 5, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to the use of BCR-ABL1 inhibitors in the treatment of CML. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 322: Nursing Strategies to Reduce Readmission Rates for Patients With Cancer Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies ONS Voice articles: Adherence to Oral Anticancer Medication Combination Therapy Shows Promise for Chronic Myeloid Leukemia The Case of the Medication Modification The Case of the Safety Session ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum articles: Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors Other ONS resources: Biomarker Database Financial Toxicity Huddle Card Tyrosine Kinase Inhibitors Huddle Card Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library National Comprehensive Cancer Network National Comprehensive Cancer Network patient resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “The IRIS study led to the approval of the BCR-ABL1 and TKI, imatinib, for CML in 2001 and completely changed the landscape of CML treatment. Then came the second-generation BCR-ABL1 TKIs: dasatinib in 2006, quickly followed by nilotinib in 2007. Thereafter came our second-generation, bosutinib, and our first approved third-generation TKI, ponatinib, both in 2012, which was a huge milestone as ponatinib overcomes resistance to the T315 I mutation, which no previously approved TKIs worked against.” TS 2:16 “The newest approved TKI, asciminib, is an allosteric inhibitor that binds to a different pocket on the BCR-ABL kinase via allosteric binding to the ABL myristoyl pocket. It's what's called a STAMP inhibitor, where STAMP stands for ‘specifically targeting the ABL myristoyl pocket.' And while all the TKIs target the BCR-ABL1 binding site, they can also inhibit different off-target kinases. And these differences in off-target inhibition are responsible for some of the different toxicities we see among the TKIs.” TS 4:51 “As a class, common toxicities include nausea; vomiting; diarrhea; cardiac toxicities, including cardiac arrhythmias and congestive heart failure; metabolic abnormalities such as hypercholesterolemia and hypertriglyceridemia; nephrotoxicity; hepatic toxicity; hemorrhaging and bleeding; as well as cytopenia. Individually, some of these agents are more likely to cause certain side effects compared to others, and there are unique toxicities associated with certain TKIs.” TS 8:10 “We've moved to using preemptive loperamide [in our clinic] for the first three days of starting treatment, because it's really hard to get patients to continue to take a medication if they have such severe diarrhea that they end up in the hospital or they're unable to leave their house. A lot of times, we will proactively give patients antiemetics and loperamide to help with the nausea, vomiting, and diarrhea. And then we can back off to an as-needed basis once they've been established on treatment. We can also use medications to help manage long-term complications that can require supportive care, such as statin therapy for high cholesterol, levothyroxine for hypothyroidism, anticoagulants for any venous thromboembolism, and antihypertensive medications for managing any new or worsening high blood pressure.” TS 12:44 “We are continually seeing these agents expand their indications to different lines of therapy, as well as more TKIs being approved for acute lymphoblastic leukemia. For example, asciminib just got approved in the frontline setting within the last year, whereas previously it was only approved in relapsed refractory setting. Last year, imatinib was the first BCR-ABL1 TKI to come out with a commercially supplied suspension option as well, which is huge in the pediatric space and [for] our adult patients who are unable to swallow tablets for other clinical reasons.” TS 21:22 “There is more information being published on the safe discontinuation of these medications with treatment-free remissions, and more information is coming out about who would be eligible and who can have the option to stop these treatments instead of having a lifelong chronic condition requiring continuous treatment. We're seeing more patients in clinical practice be able to stop BCR-ABL1 treatment, which has been a great development in CML.” TS 25:29

Advancing Innovation in Manufacturing (AIM) Centre has announced the launch of its new AI Accelerator Programme for Manufacturing Companies, a ten-week hybrid initiative designed to help businesses across Ireland understand, adopt, and scale artificial intelligence effectively. For many manufacturers, the hardest part of AI adoption is knowing where to begin. AIM's new Accelerator helps turn uncertainty into action - guiding companies toward the most valuable use cases for their operations. Starting on 1st October 2025, applications are now open to manufacturing companies of all sizes and sub-sectors. The programme is delivered by the National AI Studio for Manufacturing at AIM Centre, co-funded by the Government of Ireland and the European Union through the ERDF Northern and Western Regional Programme 2021- 27. Supporting AI Adoption in Irish Manufacturing The AI Accelerator provides a structured pathway from AI strategy to deployment, enabling participating companies to build a working demonstrator tailored to their specific needs. The programme blends online delivery with in-person events, including access to Ireland's National AI Studio for Manufacturing. Over the ten weeks (one day per week) participants will gain: • A working AI demonstrator aligned with their operations, paired with a structured use case brief to support future deployment. • Guidance on integrating AI within existing ERP and data systems. • Access to industry-specific use cases, demos, and prototypes, highlighting tangible opportunities for business transformation. • Expert guidance on governance, risk, and compliance - including EU AI Act requirements. • Insights into scaling AI across operations. AIM Centre advises teams of two people attend from each company, ensuring both strategic and technical perspectives are represented. Accreditation and Funding Support The programme is CPD-accredited by Engineers Ireland, recognising its value in professional development. To support participation, SMEs can access up to 80% funding, while larger companies can also avail of significant funding support. This ensures that businesses of all sizes can take advantage of the opportunity to future-proof their operations with AI. AIM-ing for Real Results "Irish manufacturing is at a pivotal moment in its digital transformation journey. Through this programme, we aim to demystify AI and give companies the tools, confidence, and practical outcomes they need to adopt it responsibly and at scale and with measurable business impact" - David Bermingham, Director of AI, AIM Centre. How to Apply Applications are open now. To find out more or register your interest, visit: www.aimcentre.ie/ai-accelerator-programme More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

The Joint Commission's updated accreditation manual is designed to simplify requirements, enhance clarity, and better support healthcare organizations in survey preparation. In this episode of VerifiedRx, host Carolyn Liptak is joined by Dr. Robert Campbell of the Joint Commission and Diana Scott of Vizient to unpack the most significant changes. From the shift to National Performance Goals and medication safety priorities to the latest challenges in compounding, labeling, and hazardous drug handling, the conversation highlights practical insights to help pharmacy leaders stay compliant and survey-ready.   Guest speakers: Robert Campbell, PharmD, BCSCP Sr. Director, Standards Interpretation, Accreditation Decision Management,Medication Safety Division of Accreditation and Certification Operations Joint Commission   Diana Scott, MHA, RN, CPHQ Principal, Regulatory and Accreditation Services Vizient   Host:  Carolyn Liptak, , BS Pharm, MBA   Vizient   Show Notes:  [01:16-01:51] Diana and Robert Backgrounds [01:52-02:43] Changes made to the hospital and critical access hospital manuals [02:44-03:09] Changes to the chapters themselves [03:10-04:08] National Performance Goals and elaborate on those that are relevant to medication safety and pharmacy services [04:09-05:15] The top medication management challenges [05:16-06:29] Pain management not being aligned and titration orders [06:30-06:56] Insufficient communication between pharmacists, prescribers and nurses when it comes to medication orders [06:57-08:02] Themes around labeling requirements for stored medications [08:03-08:46] Anything different in removing expired meds from patient care areas and in the pharmacy this area than previous years [08:47-10:58] Issues related to storing meds specifically per the package insert [10:59-11:55] Common issues seen inside the pharmacy regarding sterile compounding, noncompliance include hand hygiene, garbing, PPE, and cleaning and disinfecting [11:56-13:12] More specifics in those area the physical environment and facility cleanliness along with cleaning and disinfection practices [13:13-14:55] Explaination of how joint Commission defines and evaluates immediate use compounding [14:56-16:09] The minimum required elements for immediate use compounding competency [16:10-17:12] Compounding competencies besides immediate use [17:13-17:54] Expectations for environmental services training [17:55- 20:14] Concerns around hazardous drugs [20:15- 21:14] Additional information   Links | Resources: Joint Commission: THE NEW STANDARD: Accreditation 360   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

“Policies help make sure that we're giving patients the right education and discharge instructions. Radiation doesn't end when the syringe is empty. Patients go home with potential radioactive exposure. They need to know how to protect their families, what precautions to take, and what healthcare providers can do if something goes wrong—like a spill, extravasation, or even a pregnant staff member who's involved in the care. This isn't just a documentation exercise. It's about making sure every part of the system speaks the same language when it comes to safety, handling, and patient care,” ONS member Ella-Mae Shupe, MSN, RN, OCN®, nursing practice and professional development specialist for radiation oncology at Johns Hopkins Health System Sydney Kimmel Cancer Center based in Baltimore, MD, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about creating and implementing radiopharmaceutical policies and procedures.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 22, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to implementing policies and procedures to support administration of radiopharmaceuticals for cancer treatment. Episode Notes   Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 347: Care Considerations for Radiopharmaceuticals and Theranostics in Patients With Cancer Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 104: How Radiation Affects All Areas of Oncology Nursing ONS Voice articles: New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals ONS Voice oncology drug reference sheets: Lutetium Lu 177 Dotatate Lutetium Lu 177 Vipivotide Tetraxetan Radium 223 Dichloride Sodium Iodide-131 ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS course: ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing article: Nursing Telemedicine Educational Encounters: Improved Patient Satisfaction in Radiation Therapy Clinics Other ONS resources: ONS Radiation Learning Library ONS Radiation Safety: In the Home Huddle Card ONS Radiopharmaceuticals Huddle Card Daily Med Lutathera® website for healthcare professionals Pluvicto® website for healthcare professionals Xofigo® website for healthcare professionals To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “[Lutetium lu 177 vipivotide tetraxetan] has shown so effective in clinical studies that the FDA recently approved expanded use, and it can now be given prior to chemotherapy.” TS 1:56 “There are typically three parts to a radiopharmaceutical. One is a radioisotope, which emits the radiation. The second is a targeting molecule, which directs the compound to a specific site. And the third is a linker that binds the isotope to the targeting molecules securely. The targeting molecule is usually a substance that binds specifically to receptors, antigens, or metabolic pathways that are overexpressed on cancer cells.” TS 2:08  “We have an interdisciplinary team involvement. There's a physicist, nurse, and provider that confirm lab values are within normal limits. The patient meets all the clinical and safety criteria for administration. Second is an IV placement where a nurse or clin tech starts the IV and verifies a strong blood return. This is critical to avoid extravasation, which can be harmful due to the vesicant-like nature of radiopharmaceuticals. And third, our patient voids immediately before the injection, which reduces bladder radiation dose. During the administration, our provider administers the radiopharmaceutical using a shielded syringe holder to reduce radiation exposure. The physicist remains present throughout the procedure. Lead aprons are worn by any team members close to the IV site, and then the Geiger counter is used by physics to measure ionizing radiation, which is done before, during, and after the procedure.” TS 3:28 “The policy we created doesn't just address general principles. It includes very specific guidance for both [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan]. That includes everything from determining patient eligibility to completing the treatment directive, confirming patient identity, verifying delivery parameters, documenting the treatment itself, and ensuring the treatment environment is appropriate and safe. We've also built in drug- specific practices because [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan] each come with their own considerations. This includes competencies for nursing, tailored patient education for each therapy, and an extravasation checklist that outlines what to do and who's responsible for tasks if infiltration occurs.”TS 11:24 “We created two separate versions [of an attestation model], one for clinical staff and one for non-clinical staff. Why include non-clinical staff? Because the risks extend beyond just the clinical team. What if environmental services comes in to clean and the patient has urinated on the floor? Or what if dietary delivers a tray and moves a urinal without knowing the risk? Or what if transport comes in and handles an incontinent brief without awareness? Each of these scenarios has potential for contamination and exposure. And that's exactly why education for all roles matter.” TS 15:22 “These are such an exciting treatment for our patients, that's not chemotherapy, that's not radiation, and their quality of life has been amazing. We have had patients coming in that could barely walk because of the pain from bone mets and after a few treatments, they're much better. We've had PSAs go from five, six hundreds down to 0.5, so we're seeing a lot of really good options for these patients and treatment.” TS 22:09  

In this comprehensive discussion, Bryan sits down with Brad Cooper, an experienced HVAC instructor from Arkansas, and JD Kelly, a trade school graduate, to tackle one of the most pressing questions in the HVAC industry: Is trade school worth it? Rather than offering a simple yes or no answer, the trio dives deep into the nuanced factors that determine whether trade school provides real value for aspiring HVAC technicians. The conversation begins with Brad's unique perspective as both a field technician with over 20 years of experience and a current instructor who transitioned to teaching five years ago. His father's business background and the common frustration of having to "go behind people and fix stuff" motivated Brad to enter education, believing that proper training from the start could eliminate many field problems. JD brings the student perspective, having attended trade school while working full-time, which gives him insight into both the challenges and benefits of formal HVAC education. A significant portion of the discussion focuses on what to look for when evaluating trade schools. The guests emphasize that the investment in laboratory equipment and facilities often reflects the school's commitment to the program - you can tell immediately upon walking into a lab whether the institution truly prioritizes HVAC education. They stress the importance of accreditation, particularly from organizations like HVAC Excellence, which provides regular oversight and ensures schools meet industry standards. The conversation reveals that accreditation isn't just about having a certificate on the wall; it represents a school's willingness to submit to external scrutiny and maintain educational quality. The discussion also addresses the critical balance between theoretical knowledge and practical application. All three speakers agree that the most valuable trade school experiences combine classroom learning with real-world field exposure through partnerships with local contractors, apprenticeship programs, or internship opportunities. They emphasize that instructor quality matters more than having the latest equipment - a humble, field-experienced teacher who can adapt to different student skill levels and learning styles proves far more valuable than someone with extensive theoretical knowledge but limited practical experience. Topics Covered School Evaluation Criteria Laboratory equipment quality and investment levels Accreditation importance (particularly HVAC Excellence) Modern tools vs. traditional equipment balance Manufacturer partnerships and industry connections Instructor Qualifications Field experience vs. teaching credentials Importance of humility and adaptability Managing diverse skill levels in the classroom Storytelling and practical application methods Program Length and Structure Comparison of certificate programs vs. associate degrees Benefits of two-year programs for comprehensive learning Integration of on-the-job training and apprenticeships Realistic expectations for different program lengths Hands-On Learning Importance of repetition and practical experience Managing consumable materials and budget constraints Real-world equipment exposure vs. lab simulations Peer mentoring and collaborative learning approaches Student Readiness and Expectations Managing diverse student backgrounds and skill levels Realistic employer expectations for graduates The value of combining school with field experience Personal responsibility in education and continuous learning Industry Connections Importance of school-contractor partnerships Field trip opportunities and manufacturer relationships Bridging the gap between classroom and real-world application The role of apprenticeships in comprehensive training   Have a question that you want us to answer on the podcast? Submit your questions at https://www.speakpipe.com/hvacschool. Purchase your tickets or learn more about the 7th Annual HVACR Training Symposium at https://hvacrschool.com/symposium. Subscribe to our podcast on your iPhone or Android. Subscribe to our YouTube channel. Check out our handy calculators here or on the HVAC School Mobile App for Apple and Android

Explore the collaborative efforts at UAB Medicine that make National Accreditation Program for Rectal Cancer (NAPRC) accreditation successful. Robert Hollis, M.D., MSPH, and Ridley Brown, BSN, RN, explain how teamwork among surgeons, oncologists, and nurses streamlines patient navigation and care, ensuring that every aspect of a patient's journey is coordinated and efficient.

Crime is down 28% in Cape Coral, and in this episode of the Cape CopCast 'Chief's Chat,' we're breaking down exactly how it happened. Despite our growing population and increasing calls for service, we've achieved remarkable reductions across both violent and property crime categories while maintaining solvability rates well above national averages.What's our secret? Chief Anthony Sizemore says it's right there in our mission statement: "Partnering with the community to ensure the highest level of safety for all." This isn't just aspirational language—it's a practical approach that yields measurable results. When community members lock their doors, report suspicious activity, and maintain open lines of communication with officers, we create a foundation for success. Combine that with strategic deployment, advanced technology, and dedicated personnel who genuinely care about this city, and you've got a winning formula.We're particularly proud of our recent CALEA assessment—the gold standard in law enforcement accreditation that we've maintained since 1989. Assessors came to the department and conducted an exhaustive evaluation of our policies, procedures, and practices, from use of force guidelines to hiring practices that reflect our community's diversity. The result? The most successful evaluation in our department's history, with assessors recommending us as a national model in several areas. This recognition validates the significant innovations we've implemented over the past five years and confirms we're not just meeting standards—we're setting them.Looking ahead, we're expanding our ranks to keep pace with Cape Coral's growth, creating promotional opportunities from top to bottom within our organization. This combination of proven success, external validation, and internal development has created tremendous momentum. Have questions about our approach to community safety? Reach out—partnership is what makes this work, and we're just getting started.

In this episode of the EMS One-Stop podcast, host Rob Lawrence climbs back onto his soapbox to discuss two topics that directly impact on every EMS agency in America — the CAAS Ground Vehicle Standards (GVS) 4.0 and the simple, inexpensive steps we can take to stop ambulance theft. Joining Rob is longtime EMS leader and current CAAS GVS Administrator Mark Postma, who walks us through the origins of the standards, their national adoption and what's new in the latest update. From ambulance remounting, to structural safety testing, Mark explains how GVS 4.0 has evolved to keep pace with manufacturing realities, supply chain delays and operational needs. The conversation then shifts to a shared passion for protecting fleet assets. Rob and Mark dissect the shockingly frequent problem of ambulance theft and how a $200 automatic immobilization device can prevent a $250,000 vehicle from disappearing — without relying on crews to remember to lock it. Additional resources: CAAS GVS V4.0 – Ground Vehicle Standard Commission on Accreditation of Ambulance Services (CAAS) – The New Standard in Mobile Healthcare Ambulance thefts in the U.S. surge: Over 40 stolen rigs in 18 months 6 ways to safety-proof your EMS fleet Memorable quotes "It's no good going to City Council or to your board of directors on day 365 and saying, ‘I need a new truck for New Year day one' — that's not going to happen." — Rob Lawrence "The ground vehicle standard has become the standard that most vehicles are being built to and that state EMS officials are using." — Mark Postma "We spend a lot of time thinking about where things go in the box … add one more thing to your checklist: can the vehicle indeed be immobilized?" — Rob Lawrence "There's just no reason why ambulances are being stolen with the current technology that's out there." — Mark Postma Episode timeline 00:45 – Rob introduces the topic: GVS 4.0 and ambulance theft concerns 01:34 – Mark introduction and CAAS GVS role 04:11 – How the CAAS standards were developed and adopted by 35-plus states 06:09 – Comparing CAAS GVS to NFPA ambulance standards 06:48 – The rise of remounting, especially during COVID supply shortages 10:26 – Discussion of ongoing vehicle delivery delays and need for replacement planning 15:04 – What's new in GVS 4.0 — major changes and safety structure updates 19:38 – Ambulance theft statistics and the GVS anti-theft requirement 22:28 – Automatic immobilization and why manual systems fail 23:57 – Mark shares success story: zero thefts since installing devices 26:17 – Exceptions in standards and why state inspectors must enforce anti-theft 27:42 – Final thoughts on making anti-theft part of fleet planning Enjoying the show? Email editor@ems1.com to share feedback and suggest future guests. 

Office-based anesthesia (OBA) is no longer the “wild west” of healthcare. It's a thriving, highly specialized branch of anesthesia practice that's changing the way patients experience surgery. In this episode, Lynn and Garry take you inside the rapidly growing world of OBA, where 10 million procedures a year are now performed outside hospitals and ambulatory surgery centers. They explore why patients and providers are embracing this setting, the evolving safety standards, and the anesthetic techniques that make it work. Here's some of what you'll hear in this episode:

Applying to PA school without checking ARC-PA status? Not a good idea. In this episode, we're making accreditation easy to understand so you can apply confidently—and avoid surprises down the road.This can change everything for you and your PA School Application: VIP Days

“We're really using these in many, many types of malignancies. But you can see this class of drug, these monoclonal antibodies, the small molecule inhibitors, being used in colorectal cancer, ovarian cancer, renal cell carcinoma, brain cancers, hepatocellular, non-small cell lung cancer, gynecologic malignancies, so lots of different types of cancers where we're seeing these drugs used,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the vascular endothelial growth factor (VEGF) inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of VEGF inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 161: Administer Bevacizumab Infusions With Confidence ONS Voice articles: Manage Afatinib's Adverse Events to Keep Patients on Treatment Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Fruquintinib Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing article: Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Cancer cells are known to secrete factors that cause the formation of new blood vessels, and tumors need blood vessels to supply themselves with nutrients so that they can grow and metastasize. A lot of tumors overexpress these factors, so they had more of this ability to create new blood vessels. You may hear that term somewhere neo vascularization. … And also these factors can increase the permeability of blood vessels, so making them kind of leaky blood vessels. … So the thought behind it is being able to block the ability for this new blood vessel formation and to decrease that leakiness or permeability of those blood vessels.” TS 2:07 “These are drugs that are tyrosine kinase inhibitors. These are oral, small molecule drugs that are acting intracellular, so they are working within the cell to bind and prevent that downstream signaling of producing more blood vessels. So we have a number of small molecule drugs that fall into this class. Many of them target multiple types of receptors, VEGF being included, but also a lot of these drugs have other targets.” TS 7:58 “I would really say, number one, something that we very commonly see with this drug class is hypertension. Giving you an example of bevacizumab—If we look at any grade hypertension, this can be up to 67% of patients, so very common toxicity really spanning all of these agents. So something that we need to be monitoring closely for.” TS 13:24 “With that impaired wound healing, keeping that in mind, as we are planning for this agent, for patients and even sometimes with the minor surgical procedures, maybe a need for a short hold, and even for something like a catheter placement. I know and some of the providers I work with have a preference for holding for a short period of time around that as well.” TS 20:15 “I think one big area, and we've seen some of this just recently, and particularly in the hepatocellular setting, we're seeing combinations of using the VEGF inhibitor class with immunotherapy. And so I think we're going to continue to see that evolve. Even hearing about some bispecific antibodies that are in development, where they are targeting VEGF as well as PD-L1, so getting the immunotherapy and VEGF effects.” TS 24:44

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

In this episode of The P.A.S. Report, Professor Nick Giordano is joined by Adam Kissel, author of Slacking: A Guide to Ivy League Miseducation and visiting fellow for higher education reform at The Heritage Foundation. Kissel exposes the rot inside elite institutions, from Columbia University's descent into radicalism to the broader crisis of academic decline and student activism replacing scholarship. He explains why the name on a diploma too often outweighs the quality of education received, how taxpayer dollars are fueling the problem, and what states like Florida are doing to restore civic knowledge and classical learning. This conversation is essential listening for anyone concerned about the future of American higher education. Episode Highlights: How the Ivy League became more about prestige than academic excellence Why radicalism and disruptions threaten free speech and civic discourse What states can do to bring back classical education and real accountability

求职或向他人介绍自己时，常常需要介绍自己的学习和工作经历。单词 “qualification” 和 “certification” 都可以表示 “学历，资质”，但它们之间有什么不同？为什么具有类似含义的单词 “accreditation” 则不能用于描述 “个人的学历、资格证书”？听节目，跟主持人 Beth 和步理一起辨析四个可以表示 “资格，资质” 的单词。

Episode 252: Most CX maturity assessments ask how you think you're doing. This one demands proof. Erin Wallace, director of client engagement at MyCX from Bain & Company, is helping to lead a fundamental shift in how companies measure CX maturity. Most tools rely on perception-based self-assessments that reward self-promotion over progress. The Customer Experience Roadmap and Accreditation (CXRA) demands verifiable proof—evidence against 55 global, industry-backed standards. It's not always comfortable, but it's often the turning point. Bain's CXRA challenges the internal echo chamber. Erin explains how most assessments rely on surveys sent to a handful of CX insiders, producing a distorted view of reality. The CXRA demands documentation of policies, processes, behaviors, and measurable outcomes such as customer experience metrics, operational KPIs, or business results. It uses outside-in validation to confront that distortion. This isn't academic. It's where things get real. Leaders often push back. Some insist, “We're better than this.” Others admit, “We're not as good as we might think.” That tension is the point. Because CXRA doesn't just assess quality—it measures how consistently CX practices are applied across the business. That's how it exposes the “pockets of brilliance” that never scale, leaving most customers with a fragmented, uneven experience and leadership teams with a false sense of progress. For many leaders, conducting the CXRA offers clarity they've never achieved: a shared fact base, benchmarks of world-class practice, and a clear path forward. It doesn't just reveal what's missing, it builds the conviction to fix it. Guest: Erin Wallace, Director of Client Engagement, Bain & Company Host: Rob Markey, Partner, Bain & Company Give Us Feedback: Help us improve the podcast (feedback link) Key Topics Covered 01:00 – Why perception-based CX tools fall short 02:20 – What defines a successful evidence-based assessment 03:10 – The challenge with identifying “pockets of brilliance” 04:15 – How companies respond to uncomfortable truths 05:40 – Aligning leaders around what “good” really looks like 06:55 – Using 55 global standards to benchmark performance 08:10 – What Bain's CX Roadmap and Accreditation assesses 09:30 – What Erin learned at the X4 2025 Conference in Salt Lake City Time-Stamped Notable Quotes [5:00] “MyCX℠ is  a tool anyone in the industry can use, whether you're a strategic advisor, a technology implementer, or a CX practitioner. These should be things we agree on in terms of the standard of excellence for culture, capabilities, and execution.” [6:00]  “Most maturity assessments—tools to understand where you are and how you're doing with CX—are survey-based. They're perception-based. We send [them] out to a couple hundred people in the company, see what they think, and how they think they're doing with CX. You usually get back a pretty inactionable result. What's different about MyCX Roadmap and Accreditation, which is based on these global standards, is that it's an evidence-based, outside-in assessment.” [7:00] “It's an opportunity to dig in and have a conversation. And to evaluate the perception with the policy against results.” [8:00] “We look at quality, coverage, and consistency of application across the business. There could very well be a spotlight—like pockets of excellence—that are not applied across the organization in a meaningful way.” “[9:00] “What does good look like, and is that really what we aspire to accomplish? And then what will it take to get there? Because oftentimes, everyone has a different opinion of what is ‘good.' And do we really want to get there? This helps [organizations] break through and get that bigger investment unlock that's required to lead.” Learn more about Bain & Company's CX Roadmap and Accreditation process: https://www.bain.com/consulting-services/customer-strategy-and-marketing/customer-experience-transformation/mycx/ Learn more about the Global CX Standards: https://www.netpromotersystem.com/resources/cx-standards/

Republican-led states, spearheaded by Florida Governor Ron DeSantis, are launching a new accreditation body for higher education, aiming to dismantle existing standards deemed 'ideologically biased.' This move seeks to strip colleges of diversity, equity, and inclusion initiatives, replacing robust academic curricula with 'anti-woke' content focused solely on workforce metrics and conservative dogma. It's a transparent ploy to cultivate a less critically thinking populace, benefit dubious institutions like 'Trump University,' and funnel taxpayer money to politically aligned ventures. This attack on comprehensive education prioritizes control and revenue over intellectual development, turning higher learning into an echo chamber for a narrow ideology, ultimately undermining the very fabric of an informed citizenry.News Source:Universities Creating New Accreditation Agency In Some Republican StatesBy Dan Levin and Karah Rucker for Straight Arrow NewsJune 27, 2025

Plus, Linda Yaccarino steps down as CEO of X after two years on the job. And U.S. measles cases hit a 33-year high. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices